Member Info for Bladderman

We hit 157p two today - no the finish was between 145 and 148p

Patience wins the day - anything under 150p should do very well indeed. Looking forward to the news rich period. Until then the MMs are trying hard to relieve of your golden tickets. F**k em

Trying to push into close..

Adertised spread is large but real spread is pretty tight. MMs are manipulating this - it's common knowledge that we have strong news flow this month!

And at a ery attractive MCap considering the fundamentals.

A nice £17.5k straight in.

Only the seller has demoralised the share price. Once down this is over £3 easy

£3?

Do we know anything about the sellers that have taken this down from below 3p?

Global cases dropping lol. Also big business is very paranoid so testing will contiune for years

Like NCYT both have zero debt and plenty of cash now. When you scan across some of these debt ridden AIM companies worth now 100's millions making tiny profit due to inefficiencies and a highly suspect economy I'd say both of these little company's are gems.

Test test test said the WHO - who incidentally approved our Hep C test and now as we know are on their approved list! Tick tock

MMs just charged 155p for £6k as NT at 146p. They're gits!

A significant proportion suggests as a minimum half of the 50% EDITA so in real terms anywhere between 25 and 40% which equals £30M and £50M clear profit. Some aim companies are barely making profit and serving debt of 100's of millions. The economics here are exceptionally good now we are debt free. No wonder director buy is at £3.05. He's expecting a nice return too.

What's the profit margin on these sales?

£120M of sales achieved in a few months is incredible

Sales

As of 1 June 2020, sales of the Primerdesign COVID-19 test are €45 million (£40 million). In addition, Primerdesign has received orders for, or been contracted to deliver, a further €90 million (£80 million) of its COVID-19 test. Therefore, currently the total sales and confirmed orders are €135 million (£120 million).



During the second half of the year, additional COVID-19 related sales are expected from the Company's new products, Exsig™ Direct and Exsig™ Mag, and from the Company's mobile testing solution (see further detail below).



Novacyt is now selling its COVID-19 test into more than 130 countries, with the top two countries being the UK and Germany. Novacyt is also pleased with the progress it is making in the US market and expects to update the market in due course.

Sales

As of 1 June 2020, sales of the Primerdesign COVID-19 test are €45 million (£40 million). In addition, Primerdesign has received orders for, or been contracted to deliver, a further €90 million (£80 million) of its COVID-19 test. Therefore, currently the total sales and confirmed orders are €135 million (£120 million).



During the second half of the year, additional COVID-19 related sales are expected from the Company's new products, Exsig™ Direct and Exsig™ Mag, and from the Company's mobile testing solution (see further detail below).



Novacyt is now selling its COVID-19 test into more than 130 countries, with the top two countries being the UK and Germany. Novacyt is also pleased with the progress it is making in the US market and expects to update the market in due course.

Also the very recent director buy at £3.05 - when we're back at that level I'll be 25% up which is nice

£66M for a game changing company ain't bad at all Big. I've seen an awful lot of companies valued a lot more for less!!

FDA approval which is a formality will blow the doors off.

Robust and superior COVID testing product product - Indian sells lined up. £66M MCap and £8M plus cash. US DoD already a customer.

Looks like it's breaking to the upside..

Recently published by Nature Medicine which has one of the highest impact journal ratings available in the scientific research community if not the highest at 30.6!!!!